JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Seguridad y eficacia de la aspirina e Indobufen en el tratamiento de las enfermedades ateroscleróticas: revisión sistemática y metaanálisis

  • 0Department of Cardiology, Peking University People's Hospital, 11 Xizhimen S St, Xicheng District, Beijing, 100044, China, 86 13366157815.
Interactive Journal of Medical Research +

|

28 de agosto de 2025

|

28 de agosto de 2025

Ver abstracta en PubMed

Resumen

Este resumen es generado por máquina.

Indobufen ofrece una seguridad mejorada y una eficacia comparable a la de la aspirina para el tratamiento antiplaquetario en enfermedades ateroscleróticas. Reduce significativamente el sangrado y los eventos cardiovasculares adversos, incluido el infarto de miocardio.

Área De La Ciencia

  • Cardiología
  • Farmacología
  • Ensayos clínicos

Sus Antecedentes

  • La patogénesis de la trombosis aterosclerótica implica la activación de las plaquetas, por lo que la terapia antiplaquetaria es crucial.
  • La aspirina es un agente antiplaquetario estándar para las enfermedades ateroscleróticas.

Objetivo Del Estudio

  • Comparar la seguridad y eficacia de indobufén frente a la aspirina en el tratamiento antiplaquetario.
  • Evaluar los resultados, incluidos los principales eventos adversos cardiovasculares y el sangrado.

Principales Métodos

  • Metaanálisis de 18 ensayos clínicos aleatorizados y estudios observacionales prospectivos.
  • Se incluyeron 12.981 pacientes adultos con enfermedad coronaria o accidente cerebrovascular.
  • Ratios de riesgo evaluados para hemorragias, eventos cardiovasculares y mortalidad.

Principales Resultados

  • Indobufen redujo significativamente los eventos hemorrágicos (RR 0, 54) y los eventos cardiovasculares adversos (RR 0, 43) en comparación con la aspirina.
  • Indobufen también redujo el riesgo de infarto de miocardio (RR 0,60).
  • No se observaron diferencias significativas en los eventos adversos cardiovasculares y cerebrovasculares mayores o en la mortalidad.

Conclusiones

  • Indobufen demuestra una seguridad superior y una eficacia no inferior a la de la aspirina.
  • Indobufen muestra beneficios potenciales en la reducción de eventos cardiovasculares adversos y infarto de miocardio.
  • Se recomienda realizar más investigaciones con muestras de mayor tamaño.

Palabras clave:

Videos de Conceptos Relacionados

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors 01:20

644

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management 01:26

33

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Peripheral Artery Disease III: Interprofessional Care 01:27

29

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Angina IV: Management 01:26

22

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Coronary Artery Disease V: Interprofessional Care 01:27

30

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Cardiovascular Drugs: Classification based on Therapeutic Indications 01:18

3.2K

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...